Hemophilia B Gene Therapy Sustains Efficacy Over a Decade Later — 13-year follow-up shows stable factor IX expression and low bleeding rates ...

Haemophilia B Marstacimab (Hympavzi) is available on the NHS as an option for preventing bleeding episodes caused by haemophilia B in people 12 years and over who: weigh at least 35 kg have below 1% ...

A gene transfer approach to treating the bleeding disorder hemophilia B remains safe and effective long-term, as scientists from St. Jude Children's Research Hospital and University College London ...

Adeno-associated virus (AAV)–mediated gene therapy has emerged as a promising treatment for hemophilia B. Data on safety and durability from 13 years of follow-up in a cohort of patients who had ...

The recommendation of marstacimab (Hympavzi) for severe haemophilia B offers the first subcutaneous treatment and potential relief for over 200 eligible patients in England.

The Truth Behind Some Of The Most Common Myths About Haemophilia According to a doctor, dispelling myths is crucial for fostering an accurate understanding of haemophilia and the experiences of ...

APRIL marks National Hemophilia Awareness Month in the Philippines. Hemophilia is a medical condition often unseen, yet it is a deeply challenging internal battle for those who live with it.

Learn about haemophilia, a genetic blood disorder, on World Haemophilia Day 2025. Know its causes, symptoms, and preventive measures. Understand how to manage and support those affected by this ...

World Haemophilia Day is celebrated every year on April 17 and various camps are held to spread awareness about the disease.

Beyond bleeds: the power of partnership in hemophilia Perspectives from Martin Nielsen, Denmark, who lives with hemophilia B, and Wolfgang Miesbach, professor of medicine at Frankfurt University ...

World Hemophilia Day 2025 highlights global awareness and calls for inclusive care for everyone affected by bleeding disorders.

Treatment with fidanacogene elaparvovec, a recombinant adeno-associated virus (AAV) vector developed for the treatment of hemophilia B, led to sustained expression of the high-activity factor IX va ...